Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- OCUL
- Price
- 6.99
- Stock movement down
- -1.89 (-21.28%)
- Company name
- Ocular Therapeutix Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.52B
- Ent value
- 938.35M
- Price/Sales
- 29.29
- Price/Book
- 2.33
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -11.13%
- 1 year return (CAGR)
- -6.55%
- 3 year return (CAGR)
- 21.06%
- 5 year return (CAGR)
- -18.54%
- 10 year return (CAGR)
- 2.22%
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
OCUL does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 29.29 |
| Price to Book | 2.33 |
| EV to Sales | 18.06 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 217.69M |
| EPS (TTM) | -1.19 |
| FCF per share (TTM) | -0.97 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 51.95M |
| Gross profit (TTM) | 45.25M |
| Operating income (TTM) | -270.02M |
| Net income (TTM) | -265.94M |
| EPS (TTM) | -1.19 |
| EPS (1y forward) | -1.25 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 87.10% |
| Operating margin (TTM) | -519.75% |
| Profit margin (TTM) | -511.90% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 737.06M |
| Net receivables | 30.65M |
| Total current assets | 782.13M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 51.83M |
| Total assets | 808.06M |
| Accounts payable | 4.15M |
| Short/Current long term debt | 76.97M |
| Total current liabilities | 50.81M |
| Total liabilities | 153.75M |
| Shareholder's equity | 654.31M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -204.88M |
| Capital expenditures (TTM) | 12.01M |
| Free cash flow (TTM) | -216.89M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -40.64% |
| Return on Assets | -32.91% |
| Return on Invested Capital | -36.51% |
| Cash Return on Invested Capital | -29.77% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 6.41 |
| Daily high | 7.13 |
| Daily low | 6.23 |
| Daily Volume | 51.6M |
| All-time high | 43.27 |
| 1y analyst estimate | 25.58 |
| Beta | 0.90 |
| EPS (TTM) | -1.19 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 9 Mar 2026 |
Downside potential
Loading...
Downside potential data
| OCUL | S&P500 | |
| Current price drop from All-time high | -83.85% | -1.82% |
| Highest price drop | -95.19% | -56.47% |
| Date of highest drop | 16 Nov 2023 | 9 Mar 2009 |
| Avg drop from high | -76.52% | -10.84% |
| Avg time to new high | 58 days | 12 days |
| Max time to new high | 2742 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
1.52B
Marketcap category
Small-cap
Description
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and non-proliferative diabetic retinopathy; OTX-TIC, a travoprost intracameral hydrogel, which has completed phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Employees
325
Website
Investor relations
-
SEC filings
CEO
Antony Mattessich
Country
USA
City
Bedford
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page